Comprehensive medication guide to Olumiant including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$5–$500+ per month with commercial insurance; most plans place baricitinib on the specialty tier with prior authorization required. Copays range widely by plan; some plans use 20–30% coinsurance. With the Olumiant Together savings card, commercially insured patients may reduce costs to as little as $5/month. Medicare Part D patients face specialty tier costs without savings card eligibility.
Estimated Cash Pricing
$2,500–$3,000 per month for a 30-day supply at retail list price; all strengths (1 mg, 2 mg, 4 mg) are priced similarly on a per-tablet basis. No generic is available in the U.S. as of 2026. With the Olumiant Together savings card, eligible commercially insured patients may pay as little as $5/month.
Medfinder Findability Score
58/100
Summarize with AI
On this page
Olumiant is the brand name for baricitinib, an oral Janus kinase (JAK) inhibitor developed by Incyte and marketed by Eli Lilly. It comes as a once-daily tablet in three strengths: 1 mg, 2 mg, and 4 mg. As of 2026, there is no FDA-approved generic version of baricitinib available in the United States.
Olumiant is FDA-approved for three distinct conditions: moderately to severely active rheumatoid arthritis (RA) in adults who have had an inadequate response to TNF blockers (approved May 2018); severe alopecia areata in adults (approved June 2022, making it the first systemic treatment for this condition); and COVID-19 in hospitalized adults requiring supplemental oxygen or mechanical ventilation (approved May 2022).
Olumiant is only dispensed through specialty pharmacies with restricted distribution — it is not available at standard retail pharmacy chains. Most insurance plans require prior authorization before coverage is approved.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Olumiant (baricitinib) works by selectively inhibiting JAK1 and JAK2 — two proteins in the Janus kinase (JAK) family that play a central role in transmitting inflammatory immune signals inside cells. When cytokines bind to cell surface receptors, they activate JAK1 and JAK2, which then phosphorylate STAT proteins, triggering inflammatory gene expression.
By blocking JAK1 and JAK2, baricitinib interrupts this intracellular signaling cascade. In rheumatoid arthritis, this reduces the immune attack on joint tissue. In alopecia areata, it suppresses the CD8+ T-cell attack on hair follicles driven by interferon-gamma and IL-15 signaling — allowing hair to regrow. In COVID-19, it dampens the excessive cytokine-driven immune response in hospitalized patients.
Unlike biologic DMARDs (which work outside cells on specific proteins like TNF), baricitinib works inside the cell and is taken as an oral pill rather than an injection or infusion. Clinical trials showed patients with RA had significant ACR20 response improvements as early as Week 1, while alopecia areata patients showed 35–40% achieving ≥80% scalp coverage at 36 weeks.
1 mg — tablet
Lower dose; used when co-administered with probenecid or in certain dose-adjustment situations
2 mg — tablet
Standard dose for rheumatoid arthritis (2 mg once daily) and starting dose for alopecia areata
4 mg — tablet
Higher dose used for alopecia areata (especially with extensive hair loss) and COVID-19 (4 mg once daily)
Olumiant (baricitinib) is not listed on the FDA drug shortage database as of early 2026. National supply from Eli Lilly is stable. However, patients regularly encounter significant access barriers despite the absence of a formal shortage.
Olumiant is a limited-distribution specialty medication that cannot be filled at standard retail pharmacies like CVS, Walgreens, or Rite Aid. It is only dispensed through specialty pharmacy networks. Insurance plans require prior authorization — a process that can take 5–14 days — and designate specific specialty pharmacies for coverage. These system-level constraints make Olumiant harder to access than its non-shortage status would suggest.
To find Olumiant in stock near you, use medfinder — which calls specialty pharmacies in your area and identifies which ones can fill your prescription, sending results directly to you via text.
Olumiant (baricitinib) is not a controlled substance and carries no DEA scheduling. Any licensed physician, nurse practitioner (NP), or physician assistant (PA) may prescribe it. However, due to its complex safety profile — including boxed warnings for serious infections, cardiovascular events, malignancy, and thrombosis — it is most commonly initiated by specialists.
Rheumatologists — primary prescribers for rheumatoid arthritis; most experienced with DMARD monitoring requirements
Dermatologists — primary prescribers for alopecia areata; growing experience with JAK inhibitors since 2022
Primary care physicians and internists — may prescribe and manage stable RA patients, particularly in areas with limited specialty access
Nurse practitioners (NPs) and physician assistants (PAs) — may prescribe within their specialty scope in rheumatology or dermatology practices
Hospital physicians (hospitalists, infectious disease specialists, intensivists) — prescribe baricitinib for COVID-19 in inpatient settings
Telehealth is an option for both RA and alopecia areata prescriptions. Telehealth providers must be licensed in the patient's state, and pre-treatment lab work (CBC, LFTs, TB screening) is required before initiating therapy. Some insurance plans require an in-person specialist visit for initial prior authorization approval.
No. Olumiant (baricitinib) is not a DEA-scheduled controlled substance. It has no abuse potential, and there are no special DEA registration requirements for prescribers or dispensing pharmacists. Any licensed physician, nurse practitioner, or physician assistant can prescribe Olumiant without a special DEA license.
Refill restrictions for Olumiant are driven by insurance prior authorization requirements and specialty pharmacy policies — not controlled substance regulations. Most patients require an annual PA renewal and must reorder through their designated specialty pharmacy. However, there are no limitations on the number of refills from a DEA or controlled substance standpoint.
The following side effects occurred in ≥1% of patients in clinical trials:
Upper respiratory tract infections (cold, sinus infections, sore throat) — most common, ~16% at 2 mg
Nausea
Herpes simplex reactivation
Herpes zoster (shingles)
Headache
Acne and folliculitis
Hyperlipidemia (elevated cholesterol)
Elevated liver enzymes (ALT/AST)
Urinary tract infections
Serious infections (pneumonia, TB, opportunistic infections — may be fatal)
Malignancy (lymphoma, lung cancer, non-melanoma skin cancer)
Major adverse cardiovascular events: heart attack, stroke, death (elevated in patients ≥50 with CV risk factors)
Thrombosis: DVT, pulmonary embolism, arterial blood clots
GI perforation (tears in stomach or intestines)
Liver damage (hepatotoxicity)
Blood disorders: anemia, neutropenia, lymphopenia
Know what you need? Skip the search.
Xeljanz (tofacitinib)
Older JAK1/JAK3 inhibitor; first FDA-approved JAK inhibitor for RA (2012); used off-label for alopecia areata; similar safety warnings
Rinvoq (upadacitinib)
Selective JAK1 inhibitor; FDA-approved for RA, atopic dermatitis, and other autoimmune conditions; clinically comparable to baricitinib for RA
Litfulo (ritlecitinib)
FDA-approved JAK inhibitor for severe alopecia areata in adults and adolescents 12+ (2023); key alternative to Olumiant for AA
Leqselvi (deuruxolitinib)
Newer oral JAK inhibitor for severe alopecia areata in adults; FDA-approved mid-2024; commercial availability rolling out
Humira (adalimumab)
Anti-TNF biologic DMARD for RA; injectable alternative when JAK inhibitors are not appropriate; widely available with generic biosimilars
Prefer Olumiant? We can find it.
Probenecid
majorStrong OAT3 inhibitor that significantly increases baricitinib blood levels; dose must be reduced to 1 mg/day when co-administered
Other JAK inhibitors (tofacitinib, upadacitinib, ruxolitinib)
majorContraindicated — additive immunosuppression dramatically increases serious infection risk
Biologic DMARDs (adalimumab, etanercept, abatacept, etc.)
majorNot recommended — combination not studied and excessive immunosuppression risk
Azathioprine / Cyclosporine
majorPotent immunosuppressants; not recommended in combination — excessive immunosuppression risk
Live vaccines (MMR, varicella, yellow fever, live flu spray)
majorContraindicated during Olumiant therapy — impaired immune response may cause vaccine-strain infection
Methotrexate
moderateCommonly co-prescribed with Olumiant for RA; increases infection risk and GI perforation risk; requires monitoring
NSAIDs (ibuprofen, naproxen, celecoxib)
moderateIncreases risk of GI perforation when combined with Olumiant; use with caution
Corticosteroids (prednisone, methylprednisolone)
moderateIncreases infection and GI perforation risk; commonly co-prescribed as bridge therapy in RA but requires caution
Olumiant (baricitinib) is one of the most effective oral treatments available for rheumatoid arthritis and was the first systemic treatment approved for severe alopecia areata. Its once-daily oral format and three FDA-approved indications make it a versatile and important medication in rheumatology, dermatology, and hospital medicine.
Access remains the primary challenge for patients. The specialty pharmacy distribution model, prior authorization requirements, and high list price create real barriers — even in the absence of a formal shortage. The manufacturer's savings programs (Olumiant Together savings card and Lilly Cares Foundation) can dramatically reduce costs for most patients.
If you're having trouble locating your Olumiant prescription, medfinder is a paid service that calls specialty pharmacies in your area to find which ones can fill your prescription, sending results directly to you. It's one of the fastest ways to locate a specialty medication like Olumiant without spending hours on hold.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini